

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Pegcetacoplan for treating paroxysmal nocturnal
haemoglobinuria**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Pegcetacoplan is given by subcutaneous injection and can be self-administered at home. This may have implications for people who have physical or learning disabilities. Some of these people may prefer a treatment they can take at home because they struggle to travel to one of only 2 PNH specialist centres in England. Other people may struggle with the self-administration because of their disability, especially if they have manual dexterity issues, so may prefer to attend a clinic or may require help to take the injections at home.

Age and pregnancy were highlighted as protected characteristics. Inequalities may arise if different recommendations are made for children and pregnant women.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

All protected characteristics will be considered by committee when making its recommendations. However, the committee can only make recommendations within a technology's marketing authorisation.

Children and pregnant women were highlighted as populations who may be excluded from any future recommendations; however, they were excluded from the pegcetacoplan key clinical trial and may be excluded in the

technology's marketing authorisation. As such, it may not be possible for the committee to address these equality issues.

The committee will consider the potential implications of pegcetacoplan being a self-administered subcutaneous injection for people who have a disability.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): ...Linda Landells.....

Date: 8 March 2021